• 07.30 Registration (until 13.00)
  • 08.30 - 08.45 Welcome & Opening
    • Ursula Schmidt-Erfurth, Univ. Prof. Dr.
      Professor and Chair, Department of Ophthalmology and Optometry, Medical University of Vienna
      Adjunct Professor, Feinberg School of Medicine, Northwestern University Chicago 
  • 08.45 Session I – The real world
    • Chairs: Ursula Schmidt-Erfurth, Sobha Sivaprasad
    • Reasons for vision loss in the era of anti-VEGF therapy: A global perspective
      Daniel Barthelmes (Switzerland)
    • Real World Vienna: Outcomes and procedures
      Bianca Gerendas (Austria)
    • How Treat&Extend should be handled: Outcomes and retreatment criteria
      Barbara Blodi (USA)
    • Pigment epithelial detachment in diagnosis and therapy
      Michaella Goldstein (Israel)
    • Aflibercept versus laser in proliferative diabetic retinopathy
      Sobha Sivaprasad
  • 10.00 PANEL DISCUSSION: Dilemmas and solutions in the management of retinal disease
    • Moderator: Ursula Schmidt-Erfurth
    • Panelists: Daniel Barthelmes, Bailey Freund, Barbara Blodi, Michaella Goldstein, Sobha Sivaprasad
  • 10.30 Coffee Break
  • 11.00 Session II – An update in OCT
    • Chairs: Bailey Freund, Eric Moult
    • Break-throughs in quantitative optical coherence tomography
      Eric Moult (USA)
    • When OCT-A and when conventional angiography
      K. Bailey Freund (USA)
    • From research to routine
      Andreas Pollreisz (AUT)
    • The role of OCT in early AMD
      Cynthia Toth (USA)
    • Vascularized drusen and re-CNV in OCT-A
      Caroline Baumal (USA)
  • 12.15 PANEL DISCUSSION: Classical and unusual cases
    • Moderator: Bailey Freund
    • Cynthia Toth, Barbara Blodi, Sobha Sivaprasad, Pearse Keane, Michael Abramoff
  • 12.45 Lunch Break
  • 13:45 KEYNOTE LECTURE: The future is here to stay - Artificial intelligence in medicine: Present and Future
    • Bart de Witte (IBM)
  • 14.45 Session III – Future developments and innovations
    • Chairs: Michael Abramoff, Andrew Webster
    • Clinical and economic value of diabetes screening: The British experience
      Peter Scanlon (GB)
    • Screening for diabetic retinopathy – the digital way
      Michael Abramoff (USA)
    • Google in ophthalmology
      Pearse Keane (GB)
    • Probing OCT data for novel biomarkers of disease and therapy
      Sebastian Waldstein (AT)
    • The impact of whole genome sequencing on the management of retinal disorders
      Andrew Webster (GB)